Taysha Gene Therapies, Inc. (TSHA)

NASDAQ: TSHA · Real-Time Price · USD

1.610

-0.030 (-1.83%)

At close: Feb 21, 2025, 4:00 PM

1.659

+0.049 (3.04%)

After-hours: Feb 21, 2025, 4:39 PM EST

Taysha Gene Therapies Employees

Taysha Gene Therapies had 52 employees as of December 31, 2023. The number of employees decreased by 13 or -20.00% compared to the previous year.

Employees

52

Change (1Y)

-13

Growth (1Y)

-20.00%

Revenue / Employee

$190,673

Profits / Employee

-$437,923

Market Cap

329.96M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	52	-13	-20.00%
Dec 31, 2022	65	-113	-63.48%
Dec 31, 2021	178	140	368.42%
Dec 31, 2020	38	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	440,000
Johnson & Johnson	131,900
Thermo Fisher Scientific	122,000
Abbott Laboratories	114,000
AstraZeneca	89,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	72,000

Employee Rankings

TSHA News

3 days ago - Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26 - GlobeNewsWire
15 days ago - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
25 days ago - Taysha Gene Therapies Is Showing Promise For Rett Syndrome - Seeking Alpha
3 months ago - Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
3 months ago - Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Transcript - Seeking Alpha
3 months ago - Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
4 months ago - Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress - GlobeNewsWire
4 months ago - Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data - Seeking Alpha